3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02012933|
Recruitment Status : Available
First Posted : December 17, 2013
Last Update Posted : April 21, 2015
Lambert-Eaton Myasthenic Syndrome (LEMS) is a rare autoimmune disorder which affects the nerve-muscle junction. The major symptoms of LEMS are progressive muscle weakness. Many patients experience other symptoms like dry mouth or impotence. Congenital Myasthenia (CM) is an inherited disorder with similar affects and symptoms.
3,4-Diaminopyridine (DAP) is an experimental drug that has improved strength in some subjects with (LEMS). There are no other accepted treatments for LEMS and DAP has relatively few side effects.
|Condition or disease||Intervention/treatment|
|Lambert-Eaton Myasthenic Syndrome (LEMS) Congenital Myasthenia (CM)||Drug: 3,4-diaminopyridine|
|Study Type :||Expanded Access|
|Official Title:||3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenia|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02012933
|Contact: Diana Dimitrova, PhDfirstname.lastname@example.org|
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|Contact: Diana Dimitrova, PhD 503-494-7269 email@example.com|
|Principal Investigator: Tessa Marburger, MD|
|Sub-Investigator: Julie Khoury, MD|